Lewis Susan J, Mueller Bruce A
Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI, USA
J Intensive Care Med. 2016 Mar;31(3):164-76. doi: 10.1177/0885066614555490. Epub 2014 Oct 16.
Increasing evidence suggests that antibiotic dosing in critically ill patients with acute kidney injury (AKI) often does not achieve pharmacodynamic goals, and the continued high mortality rate due to infectious causes appears to confirm these findings. Although there are compelling reasons why clinicians should use more aggressive antibiotic dosing, particularly in patients receiving aggressive renal replacement therapies, concerns for toxicity associated with higher doses are real. The presence of multisystem organ failure and polypharmacy predispose these patients to drug toxicity. This article examines the pharmacokinetic and pharmacodynamic consequences of critical illness, AKI, and renal replacement therapy and describes potential solutions to help clinicians give "enough but not too much" in these very complicated patients.
越来越多的证据表明,急性肾损伤(AKI)的重症患者使用抗生素的剂量常常无法达到药效学目标,而因感染导致的持续高死亡率似乎证实了这些发现。尽管有令人信服的理由让临床医生采用更积极的抗生素给药方式,尤其是在接受积极肾脏替代治疗的患者中,但对高剂量相关毒性的担忧是切实存在的。多系统器官衰竭和多种药物联合使用的情况使这些患者易发生药物毒性。本文探讨了危重病、急性肾损伤和肾脏替代治疗对药代动力学和药效学的影响,并描述了一些潜在的解决方案,以帮助临床医生在这些非常复杂的患者中做到“足够但不过量”给药。